Oral drugs used to treat persistent pulmonary hypertension of the newborn

References

• Ostrea EM, Villanueva-Uy ET, Natarajan G, et al. Persistent pulmonary hypertension of the newborn: pathogenesis, etiology, and management. Paediatr Drugs. 2006;8(3):179–188.
   PubMedGoogle Scholar
• Steurer MA, Jelliffe-Pawlowski LL, Baer RJ, et al. Persistent pulmonary hypertension of the newborn in late preterm and term infants in California. Pediatrics. 2017;139(1):e20161165.
   PubMed Web of Science ®Google Scholar
• Nakwan N, Jain S, Kumar K, et al. An Asian multicenter retrospective study on persistent pulmonary hypertension of the newborn: incidence, etiology, diagnosis, treatment and outcome. J Matern Fetal Neonatal Med. 2020 Jun;33(12):2032–2037.
   PubMedGoogle Scholar
• Vargas-Origel A, Gómez-Rodríguez G, Aldana-Valenzuela C, et al. The use of sildenafil in persistent pulmonary hypertension of the newborn. Am J Perinatol. 2010;27(3):225–230.
   PubMed Web of Science ®Google Scholar
• Lakshminrusimha S, Mathew B, Leach CL. Pharmacologic strategies in neonatal pulmonary hypertension other than nitric oxide. Semin Perinatol. 2016 Apr;40(3):160–173.
   PubMed Web of Science ®Google Scholar
• Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004;351(14):1425–1436.
   PubMed Web of Science ®Google Scholar
• Pedersen J, Hedegaard ER, Simonsen U, et al. Current and future treatments for persistent pulmonary hypertension in the newborn. Basic Clin Pharmacol Toxicol. 2018;123(4):392–406.
   PubMed Web of Science ®Google Scholar
• Yaseen H, Darwich M, Hamdy H. Is sildenafil an effective therapy in the management of persistent pulmonary hypertension? J Clin Neonatol. 2012;1(4):171.
   PubMedGoogle Scholar
• Nelin LD, Potenziano JL. Inhaled nitric oxide for neonates with persistent pulmonary hypertension of the newborn in the CINRGI study: time to treatment response. BMC Pediatr. 2019;19(1):1717.
   Google Scholar
• Subhedar NV, Jauhari P, Natarajan R. Cost of inhaled nitric oxide therapy in neonates. Lancet. 2002;359(9319):1781–1782.
   PubMed Web of Science ®Google Scholar
• Nakwan N, Choksuchat D, Saksawad R, et al. Successful treatment of persistent pulmonary hypertension of the newborn with bosentan. Acta Paediatr. 2009;98(10):1683–1685.
   PubMed Web of Science ®Google Scholar
• Heal C, Spencer S. Methaemoglobinaemia with high-dose nitric oxide administration. Acta Paediatr. 1995;84(11):1318.
   PubMed Web of Science ®Google Scholar
• Lundin S, Mang H, Smithies M, et al. Inhalation of nitric oxide in acute lung injury: results of a European multicentre study. The European study group of inhaled nitric oxide. Intensive Care Med. 1999;25(9):911–919.
   PubMed Web of Science ®Google Scholar
• George TN, Johnson KJ, Bates JN, et al. The effect of inhaled nitric oxide therapy on bleeding time and platelet aggregation in neonates. J Pediatr. 1998;132(4):731–734.
   PubMed Web of Science ®Google Scholar
• Markova SM, De Marco T, Bendjilali N, et al. Association of CYP2C9*2 with bosentan-induced liver injury. Clin Pharmacol Ther. 2013;94(6):678–686.
   PubMed Web of Science ®Google Scholar
• Spence R, Mandagere A, Dufton C, et al. Pharmacokinetics and safety of ambrisentan in combination with sildenafil in healthy volunteers. J Clin Pharmacol. 2008;48(12):1451–1459.
   PubMed Web of Science ®Google Scholar
• Kumar P, Thudium E, Laliberte K, et al. A comprehensive review of treprostinil pharmacokinetics via four routes of administration. Clin Pharmacokinet. 2016;55(12):1495–1505.
   PubMed Web of Science ®Google Scholar
• Croom KF, Curran MP. Sildenafil: a review of its use in pulmonary arterial hypertension. Drugs. 2008;68(3):383–397.
   PubMed Web of Science ®Google Scholar
• Nakwan N, Nakwan N, Wannaro J. Persistent pulmonary hypertension of the newborn successfully treated with beraprost sodium: a retrospective chart review. Neonatology. 2011;99(1):32–37.
   PubMed Web of Science ®Google Scholar
• Simonneau G, Torbicki A, Hoeper MM, et al. Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J. 2012;40(4):874–880.
   PubMed Web of Science ®Google Scholar
• Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332(6163):411–415.
   PubMed Web of Science ®Google Scholar
• Barnes K, Turner A. Endothelin converting enzyme is located on α-actin filaments in smooth muscle cells. Cardiovasc Res. 1999;42(3):814–822.
   PubMed Web of Science ®Google Scholar
• Hu J, Discher DJ, Bishopric NH, et al. Hypoxia regulates expression of the endothelin-1 gene through a proximal hypoxia-inducible factor-1 binding site on the antisense strand. Biochem Biophys Res Commun. 1998;245(3):894–899.
   PubMed Web of Science ®Google Scholar
• Sakurai T, Yanagisawa M, Takuwat Y, et al. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature. 1990;348(6303):732–735.
   PubMed Web of Science ®Google Scholar
• Ivy DD, Parker TA, Ziegler JW, et al. Prolonged endothelin A receptor blockade attenuates chronic pulmonary hypertension in the ovine fetus. J Clin Invest. 1997;99(6):1179–1186.
   PubMed Web of Science ®Google Scholar
• Kumar P, Kazzi NJ, Shankaran S. Plasma immunoreactive endothelin-1 concentrations in infants with persistent pulmonary hypertension of the newborn. Am J Perinatol. 1996;13(6):335–341.
   PubMed Web of Science ®Google Scholar
• Rosenberg AA, Kennaugh J, Koppenhafer SL, et al. Elevated immunoreactive endothelin-1 levels in newborn infants with persistent pulmonary hypertension. J Pediatr. 1993;123(1):109–114.
   PubMed Web of Science ®Google Scholar
• Goissen C, Ghyselen L, Tourneux P, et al. Persistent pulmonary hypertension of the newborn with transposition of the great arteries: successful treatment with bosentan. Eur J Pediatr. 2008;167(4):437–440.
   PubMed Web of Science ®Google Scholar
• Ramani GV, Park MH. Update on the clinical utility of sildenafil in the treatment of pulmonary arterial hypertension. Drug Des Devel Ther. 2010;4:61–70.
   PubMed Web of Science ®Google Scholar
• Kots AY, Martin E, Sharina IG, et al. A short history of cGMP, guanylyl cyclases, and cGMP-dependent protein kinases. Handb Exp Pharmacol. 2009;191:1–14.
   Google Scholar
• Essayan DM. Cyclic nucleotide phosphodiesterases. J Allergy Clin Immunol. 2001;108(5):671–680.
   PubMed Web of Science ®Google Scholar
• Wharton J, Strange JW, Moller GM, et al. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med. 2005;172(1):105–113.
   PubMed Web of Science ®Google Scholar
• Motte S, McEntee K, Naeije R. Endothelin receptor antagonists. Pharmacol Ther. 2006;110(3):386–414.
   PubMed Web of Science ®Google Scholar
• Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 2001;358(9288):1119–1123.
   PubMed Web of Science ®Google Scholar
• Radicioni M, Bruni A, Camerini P. Combination therapy for life-threatening pulmonary hypertension in a premature infant: first report on bosentan use. Eur J Pediatr. 2011;170(8):1075–1078.
   PubMed Web of Science ®Google Scholar
• Maneenil G, Thatrimontrichai A, Janjindamai W, et al., Effect of bosentan therapy in persistent pulmonary hypertension of the newborn. Pediatr Neonatol. 59(1): 58–64. 2018. .
   PubMed Web of Science ®Google Scholar
• Mohamed WA, Ismail M. A randomized, double-blind, placebo-controlled, prospective study of bosentan for the treatment of persistent pulmonary hypertension of the newborn. J Perinatol. 2012;32(8):608–613.
   PubMed Web of Science ®Google Scholar
• Steinhorn RH, Fineman J, Kusic-Pajic A, et al. Bosentan as adjunctive therapy for persistent pulmonary hypertension of the newborn: results of the randomized multicenter placebo-controlled exploratory trial. J Pediatr. 2016;177(90–96.e3):90–96.e3.
   Google Scholar
• Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353(20):2148–2157.
   PubMed Web of Science ®Google Scholar
• Goldstein I, Lue TF, Padma-Nathan H, et al. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil study group. N Engl J Med. 1998;338(20):1397–1404.
   PubMed Web of Science ®Google Scholar
• Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2016;37(1):67–119.
   PubMed Web of Science ®Google Scholar
• FDA US. FDA drug safety communication: FDA clarifies warning about pediatric use of revatio (sildenafil) for pulmonary arterial hypertension. FDA. 2014. [cited 2014 Mar 31].http://www.fda.gov/Drugs/DrugSafety/ucm390876.htm
   Google Scholar
• Latini G, Rosati E, De Felice C, et al. Sildenafil administration to a patient with refractory persistent pulmonary hypertension of the newborn. J Matern Fetal Neonatal Med. 2008;21(9):671–673.
   PubMed Web of Science ®Google Scholar
• König K, Henschke P. Successful weaning of nitric oxide facilitated by a single dose of sildenafil in a baby with persistent pulmonary hypertension of the newborn. Pediatr Pulmonol. 2009;44(8):837.
   PubMed Web of Science ®Google Scholar
• Gamboa D, Robbins D, Saba Z. Bleeding after circumcision in a newborn receiving sildenafil. Clin Pediatr (Phila). 2007;46(9):842–843.
   PubMed Web of Science ®Google Scholar
• Lavie-Nevo K, Harris KC, Ting JY. Use of sildenafil in an infant with persistent pulmonary hypertension secondary to lung and renal hypoplasia–a case report. BMC Pediatr. 2019;19(1):1–4.
   PubMed Web of Science ®Google Scholar
• Cavallaro G, Agazzani E, Andaloro L, et al. Sildenafil and nitric oxide inhalation in neonatal pulmonary hypertension. Three case reports. Pediatr Med Chir. 2008;30(3):149–155.
   PubMedGoogle Scholar
• Demir N, Peker E, Ece I, et al. A rare cause of persistent pulmonary hypertension resistant to therapy in the newborn: short-Rib polydactyly syndrome. Case Rep Pulmonol. 2015;2015:274639.
   PubMedGoogle Scholar
• Chaudhari M, Vogel M, Wright C, et al. Sildenafil in neonatal pulmonary hypertension due to impaired alveolarisation and plexiform pulmonary arteriopathy. Arch Dis Child Fetal Neonatal Ed. 2005;90(6):F527–8.
   PubMed Web of Science ®Google Scholar
• Juliana AE, Abbad FC. Severe persistent pulmonary hypertension of the newborn in a setting where limited resources exclude the use of inhaled nitric oxide: successful treatment with sildenafil. Eur J Pediatr. 2005;164(10):626–629.
   PubMed Web of Science ®Google Scholar
• Filan PM, McDougall PN, Shekerdemian LS. Combination pharmacotherapy for severe neonatal pulmonary hypertension. J Paediatr Child Health. 2006;42(4):219–220.
   PubMed Web of Science ®Google Scholar
• Kecskes Z, Kent A, Reynolds G. Treatment of pulmonary hypertension with sildenafil in a neonate with spondyloepiphyseal dysplasia congenita. J Matern Fetal Neonatal Med. 2006;19(9):579–582.
   PubMed Web of Science ®Google Scholar
• Mersal A, Attili I, Alkhotani A. Severe neonatal pulmonary hypertension secondary to antenatal maternal diclofenac ingestion reversed by inhaled nitric oxide and oral sildenafil. Ann Saudi Med. 2007;27(6):448–449.
   PubMed Web of Science ®Google Scholar
• Simiyu DE, Okello C, Nyakundi EG, et al. Sildenafil in management of persistent pulmonary hypertension of the newborn: report of two cases. East Afr Med J. 2006;83(6):337–340.
   PubMedGoogle Scholar
• Engelbrecht AL. Sildenafil in the management of neonates with PPHN: A rural regional hospital experience. SAJCH. 2008;2:4.
   Google Scholar
• Son SB, Kim KA, Yun SY, et al. Oral sildenafil in persistent pulmonary hypertension of the newborn. Korean Soc Neonatol. 2011;18(1):124.
   Google Scholar
• Hussain AS, Ali R, Ahmed S, et al. Oral sildenafil use in neonates with persistent pulmonary hypertension of newborn. J Ayub Med Coll Abbottabad. 2017;29(4):677–680.
   PubMedGoogle Scholar
• Alnemri AM. Black lung persistent pulmonary hypertension of the newborn. Saudi experience with sildenafil and nitric oxide. Saudi Med J. 2017;38(1):97–100.
   PubMed Web of Science ®Google Scholar
• Kahveci H, Yilmaz O, Avsar UZ, et al. Oral sildenafil and inhaled iloprost in the treatment of pulmonary hypertension of the newborn. Pediatr Pulmonol. 2014;49(12):1205–1213.
   PubMed Web of Science ®Google Scholar
• Castillo J, Herrera R, Concha E, et al. Oral sildenafil treatment as an alternative to inhaled no therapy for persistent pulmonary hypertension of the newborn. Pediatr Res. 2005;58(2):420420.
   Web of Science ®Google Scholar
• Sayed A, Bisheer N. Outcome of oral sildenafil in neonatal persistent pulmonary hypertension of non-cardiac causes. J Neonatal Perinatal Med. 2015;8(3):215–220.
   PubMedGoogle Scholar
• Khorana M, Yookaseam T, Layangool T, et al. Outcome of oral sildenafil therapy on persistent pulmonary hypertension of the newborn at queen sirikit national institute of child health. J Med Assoc Thai. 2011 Aug;94(Suppl 3):S64–73.
   PubMedGoogle Scholar
• Abdel Mohsen AH, Amin AS. Risk factors and outcomes of persistent pulmonary hypertension of the newborn in neonatal intensive care unit of Al-minya university hospital in egypt. J Clin Neonatol. 2013 Apr;2(2):78–82.
   PubMedGoogle Scholar
• Prithviraj D, Reddy B, Shetty A, et al. Oral sildenafil in persistent pulmonary hypertension of the newborn in invasive and non-invasive ventilated babies-its effect on oxygenation indices. Int J Sci Study. 2016 May;4(2):203–209.
   Google Scholar
• Steinhorn RH, Kinsella JP, Pierce C, et al., Intravenous sildenafil in the treatment of neonates with persistent pulmonary hypertension. J Pediatr. 155(6): 841–847 e1. 2009. .
   PubMed Web of Science ®Google Scholar
• Baquero H, Soliz A, Neira F, et al. Oral sildenafil in infants with persistent pulmonary hypertension of the newborn: a pilot randomized blinded study. Pediatrics. 2006 Apr;117(4):1077–1083.
   PubMed Web of Science ®Google Scholar
• Torres RH, González PC, Castillo JH, et al. Oral sildenafil as an alternative treatment in the persistent pulmonary hypertension in newborns. Revista Mexicana de Pediatria. 2006; 73(4): 159–163.
   Google Scholar
• Uslu S, Kumtepe S, Bulbul A, et al. A comparison of magnesium sulphate and sildenafil in the treatment of the newborns with persistent pulmonary hypertension: a randomized controlled trial. J Trop Pediatr. 2011 Aug;57(4):245–250.
   PubMed Web of Science ®Google Scholar
• Shaltout F, Hegazy R, Aboulghar H, et al. Magnesium sulphate versus sildenafil in the treatment of persistent pulmonary hypertension of the newborn. Int J Clin Pediatr. 2012; 1(1): 19–24.
   Google Scholar
• Al Omar S, Salama H, Al Hail M, et al. Effect of early adjunctive use of oral sildenafil and inhaled nitric oxide on the outcome of pulmonary hypertension in newborn infants. A feasibility study. J Neonatal Perinatal Med. 2016;9(3):251–259.
   PubMedGoogle Scholar
• Galie N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009;119(22):2894–2903.
   PubMed Web of Science ®Google Scholar
• Takatsuki S, Calderbank M, Ivy DD. Initial experience with tadalafil in pediatric pulmonary arterial hypertension. Pediatr Cardiol. 2012 Jun;33(5):683–688.
   PubMed Web of Science ®Google Scholar
• Alipour MR, Lookzadeh MH, Namayandeh SM, et al. Comparison of tadalafil and sildenafil in controlling neonatal persistent pulmonary hypertension. Iran J Pediatr. 2017;27:1.
   Web of Science ®Google Scholar
• Humbert M, Segal ES, Kiely DG, et al. Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur Respir J. 2007 Aug;30(2):338–344.
   PubMed Web of Science ®Google Scholar
• Dingemanse J, van Giersbergen PL. Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin Pharmacokinet. 2004;43(15):1089–1115.
   PubMed Web of Science ®Google Scholar
• Dingemanse J, Bodin F, Weidekamm E, et al. Influence of food intake and formulation on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. J Clin Pharmacol. 2002 Mar;42(3):283–289.
   PubMed Web of Science ®Google Scholar
• Parekh JM, Shah DK, Sanyal M, et al. Development of an SPE-LC-MS/MS method for simultaneous quantification of bosentan and its active metabolite hydroxybosentan in human plasma to support a bioequivalence study. J Pharm Biomed Anal. 2012 Nov;70:462–470.
   PubMed Web of Science ®Google Scholar
• Barst RJ, Ivy D, Dingemanse J, et al. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther. 2003 Apr;73(4):372–382.
   PubMed Web of Science ®Google Scholar
• Weber C, Schmitt R, Birnboeck H, et al. Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects. Clin Pharmacol Ther. 1996 Aug;60(2):124–137.
   PubMed Web of Science ®Google Scholar
• van Giersbergen PL, Popescu G, Bodin F, et al. Influence of mild liver impairment on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. J Clin Pharmacol. 2003 Jan;43(1):15–22.
   PubMed Web of Science ®Google Scholar
• Lacroix D, Sonnier M, Moncion A, et al. Expression of CYP3A in the human liver–evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. Eur J Biochem. 1997 Jul 15;247(2):625–634.
   PubMedGoogle Scholar
• Koukouritaki SB, Manro JR, Marsh SA, et al. Developmental expression of human hepatic CYP2C9 and CYP2C19. J Pharmacol Exp Ther. 2004 Mar;308(3):965–974.
   PubMed Web of Science ®Google Scholar
• Nichols DJ, Muirhead GJ, Harness JA. Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. Br J Clin Pharmacol. 2002;53:5S–12S.
   PubMed Web of Science ®Google Scholar
• Grossman EB, Swan SK, Muirhead GJ, et al. The pharmacokinetics and hemodynamics of sildenafil citrate in male hemodialysis patients. Kidney Int. 2004 Jul;66(1):367–374.
   PubMed Web of Science ®Google Scholar
• Warrington JS, Shader RI, von Moltke LL, et al. In vitro biotransformation of sildenafil (Viagra): identification of human cytochromes and potential drug interactions. Drug Metab Dispos. 2000 Apr;28(4):392–397.
   PubMed Web of Science ®Google Scholar
• Walker DK, Ackland MJ, James GC, et al. Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. Xenobiotica. 1999 Mar;29(3):297–310.
   PubMed Web of Science ®Google Scholar
• Mukherjee A, Dombi T, Wittke B, et al. Population pharmacokinetics of sildenafil in term neonates: evidence of rapid maturation of metabolic clearance in the early postnatal period. Clin Pharmacol Ther. 2009 Jan;85(1):56–63.
   PubMed Web of Science ®Google Scholar
• Forgue ST, Patterson BE, Bedding AW, et al. Tadalafil pharmacokinetics in healthy subjects. Br J Clin Pharmacol. 2006 Mar;61(3):280–288.
   PubMed Web of Science ®Google Scholar
• Kim J-S, Kim M-S, Baek I-H. Enhanced bioavailability of tadalafil after intranasal administration in Beagle dogs. Pharmaceutics. 2018;10(4):187.
   Web of Science ®Google Scholar
• Kohno H, Ichida F, Hirono K, et al. Plasma concentrations of tadalafil in children with pulmonary arterial hypertension. Ther Drug Monit. 2014 Oct;36(5):576–583.
   PubMed Web of Science ®Google Scholar
• Nakau K, Sugimoto M, Oka H, et al. Pharmacokinetics of drugs for pediatric pulmonary hypertension. Pediatr Int. 2016 Nov;58(11):1112–1117.
   PubMed Web of Science ®Google Scholar
• King SH, Hallock M, Strote J, et al. Tadalafil-associated priapism. Urology. 2005;66(2):432. e15-432. e18.
   PubMed Web of Science ®Google Scholar
• Forgue ST, Phillips DL, Bedding AW, et al. Effects of gender, age, diabetes mellitus and renal and hepatic impairment on tadalafil pharmacokinetics. Br J Clin Pharmacol. 2007 Jan;;63(1):24–35.
   PubMed Web of Science ®Google Scholar
• Sanchez Luna M, Franco ML, Bernardo B. Therapeutic strategies in pulmonary hypertension of the newborn: where are we now? Curr Med Chem. 2012;19(27):4640–4653.
   PubMed Web of Science ®Google Scholar
• Barst RJ, Beghetti M, Pulido T, et al. STARTS-2: long-term survival with oral sildenafil monotherapy in treatment-naive pediatric pulmonary arterial hypertension. Circulation. 2014 May 13;129(19):1914–1923.
   PubMed Web of Science ®Google Scholar
• Nakwan N, Chaiwiriyawong P. An international survey on persistent pulmonary hypertension of the newborn: A need for an evidence-based management. J Neonatal Perinatal Med. 2016 Sep 16;9(3):243–250.
   PubMedGoogle Scholar
• Cote RH. Characteristics of photoreceptor PDE (PDE6): similarities and differences to PDE5. Int J Impot Res. 2004 Jun;16(Suppl 1):S28–33.
   PubMedGoogle Scholar
• Marsh CS, Marden B, Newsom R. Severe retinopathy of prematurity (ROP) in a premature baby treated with sildenafil acetate (Viagra) for pulmonary hypertension. Br J Ophthalmol. 2004 Feb;88(2):306–307.
   PubMed Web of Science ®Google Scholar
• Samiee-Zafarghandy S, Smith PB, van den Anker JN. Safety of sildenafil in infants*. Pediatr Crit Care Med. 2014 May;15(4):362–368.
   PubMed Web of Science ®Google Scholar
• Luecke C, McPherson C. Treatment of persistent pulmonary hypertension of the newborn: use of pulmonary vasodilators in term neonates. Neonatal Netw. 2017 May 1;36(3):160–168.
   PubMed Web of Science ®Google Scholar
• Beghetti M, Hoeper MM, Kiely DG, et al. Safety experience with bosentan in 146 children 2-11 years old with pulmonary arterial hypertension: results from the European postmarketing surveillance program. Pediatr Res. 2008 Aug;64(2):200–204.
   PubMed Web of Science ®Google Scholar
• Simonneau G, Galie N, Jansa P, et al. Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients. Int J Cardiol. 2014;172(2):332–339.
   PubMed Web of Science ®Google Scholar
• Roberts KE, Preston IR. Safety and tolerability of bosentan in the management of pulmonary arterial hypertension. Drug Des Devel Ther. 2009 Sep;21(3):111–118.
   Google Scholar
• Foller M, Mahmud H, Qadri SM, et al. Endothelin B receptor stimulation inhibits suicidal erythrocyte death. Faseb J. 2010 Sep;;24(9):3351–3359.
   PubMed Web of Science ®Google Scholar
• Zeidel ML, Brady HR, Kone BC, et al. Endothelin, a peptide inhibitor of Na(+)-K(+)-ATPase in intact renaltubular epithelial cells. Am J Physiol. 1989 Dec;257(6 Pt 1):C1101–7.
   PubMedGoogle Scholar
• Shiva A, Shiran M, Rafati M, et al. Oral tadalafil in children with pulmonary arterial hypertension. Drug Res (Stuttg). 2016 Jan;66(1):7–10.
   PubMed Web of Science ®Google Scholar
• Kotera J, Mochida H, Inoue H, et al. Avanafil, a potent and highly selective phosphodiesterase-5 inhibitor for erectile dysfunction. J Urol. 2012 Aug;188(2):668–674.
   PubMed Web of Science ®Google Scholar
• Wang R, Burnett AL, Heller WH, et al. Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability. J Sex Med. 2012 Aug;9(8):2122–2129.
   PubMed Web of Science ®Google Scholar
• Burgess G, Hoogkamer H, Collings L, et al. Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil. Eur J Clin Pharmacol. 2008;64(1):43–50.
   PubMed Web of Science ®Google Scholar
• Wrishko RE, Dingemanse J, Yu A, et al. Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects. J Clin Pharmacol. 2008 May;48(5):610–618.
   PubMed Web of Science ®Google Scholar
• Dewhurst C, Ibrahim H, Göthberg S, et al. Use of inhaled nitric oxide in the new born period: results from the European inhaled nitric oxide registry. Acta Paediatr. 2010 Jun;99(6):854–860.
   PubMed Web of Science ®Google Scholar
• Woolard RH, Carty K, Wirtz P, et al. Research fundamentals: follow-up of subjects in clinical trials: addressing subject attrition. Acad Emerg Med. 2004 Aug;11(8):859–866.
   PubMed Web of Science ®Google Scholar
• Sun H, Stockbridge N, Ariagno RL, et al. Reliable and developmentally appropriate study end points are needed to achieve drug development for treatment of pediatric pulmonary arterial hypertension. J Perinatol. 2016 Dec;36(12):1029–1033.
   PubMed Web of Science ®Google Scholar
• Reynolds EW, Ellington JG, Vranicar M, et al. Brain-type natriuretic peptide in the diagnosis and management of persistent pulmonary hypertension of the newborn. Pediatrics. 2004 Nov;114(5):1297–1304.
   PubMed Web of Science ®Google Scholar
• Frantz RP, McDevitt S, Walker S. Baseline NT-proBNP correlates with change in 6-minute walk distance in patients with pulmonary arterial hypertension in the pivotal inhaled treprostinil study TRIUMPH-1. J Heart Lung Transplant. 2012 Aug;31(8):811–816.
   PubMed Web of Science ®Google Scholar